KRTX - Karuna Therapeutics trims losses after $14M insider purchase
- Clinical-stage biotech Karuna Therapeutics ( NASDAQ: KRTX ) reversed a sharp decline on Friday after a director of the company disclosed an insider purchase of company shares worth more than $14M.
- According to the regulatory filing, Healy James, a General Partner of Sofinnova Investments has bought 120K Karuna ( KRTX ) shares at $122.80 apiece for a total value of $14.7M.
- The purchases were made through a series of transaction on Wednesday and Thursday on behalf of Sofinnova Synergy Master Fund LP and Sofinnova Venture Partners X, LP.
- In terms of current analyst ratings, Karuna ( KRTX ) commands a Strong Buy recommendation on Wall Street.
For further details see:
Karuna Therapeutics trims losses after $14M insider purchase